##罗氏诊断加码中国市场，苏州新基地将成亚太研发制造中心
**中新社苏州8月21日电 (记者钟升)** 罗氏诊断亚太试剂及仪器设备生产和研发基地新投资项目21日在苏州工业园区签约。该项目首期投资30亿元人民币，占地55亩，建筑面积约6万平方米，预计于2028年正式投产。这是罗氏诊断在华最大单笔投资项目，标志着该公司将进一步深耕中国市场，并将其苏州基地打造成为亚太地区的研发制造中心。
瑞士罗氏集团是全球领先的生物医药企业，其诊断业务在全球范围内占据重要地位。罗氏诊断于2015年在苏州工业园区设立生产基地，并在之后陆续启动亚太研发中心、系统试剂制造基地等项目。此次新项目的落地，将进一步完善罗氏诊断在苏州的产业链布局，并为其在亚太地区的业务发展提供强力支撑。
据了解，新项目建成后，罗氏诊断亚太生产基地和研发中心计划投产约400种试剂和仪器产品，累计投资将达10亿瑞士法郎。罗氏诊断亚太生产基地和研发中心总经理马凯表示，苏州的新投资项目将为高质量产品进入中国市场提供更多助力，并确保亚太地区的可持续供应。
罗氏诊断中国总经理姚国樑强调，中国是罗氏诊断在全球最具战略意义的市场之一。该公司将坚持“在中国、为中国”的理念，持续投资本土创新、研发和生产，为中国患者量身定制创新解决方案。
瑞士驻华大使白瑞谊在致辞中表示，苏州等中国城市的开放包容与优秀营商环境，吸引了众多瑞士企业落户中国并蓬勃发展。他相信，随着瑞中两国关系的不断深化，未来将有更多瑞士企业在中国取得成功。
罗氏诊断此次在苏州的投资，不仅体现了该公司对中国市场的信心，也反映了中国生物医药产业的快速发展和巨大的市场潜力。未来，随着中国医疗体系的不断完善和人民生活水平的提高，生物医药产业将迎来更加广阔的发展空间。
英语如下：
##Roche Diagnostics Invests 3 Billion Yuan in Suzhou to Build Asia-Pacific’s Largest Production and R&D Base
**Keywords:** Roche Diagnostics,Suzhou Investment, Asia-Pacific Base
**News Content:**
**Suzhou, August 21 (CNS)** – Roche Diagnostics’ new investment projectfor its Asia-Pacific reagents and instrument production and R&D base was signed in Suzhou Industrial Park on Monday. The project, with an initial investment of3 billion yuan, covers 55 mu (about 9 acres) and will have a construction area of approximately 60,000 square meters. It is expected to begin production in 2028. Thisis Roche Diagnostics’ largest single investment project in China, signifying the company’s commitment to further cultivate the Chinese market and establish its Suzhou base as a regional R&D and manufacturing hub for Asia-Pacific.
Swiss-based RocheGroup is a global leader in biopharmaceutical companies, with its diagnostics business holding a significant position worldwide. Roche Diagnostics established its production base in Suzhou Industrial Park in 2015 and subsequently launched projects for an Asia-Pacific R&D center and a system reagent manufacturing base. The new project will further enhance RocheDiagnostics’ industrial chain layout in Suzhou and provide strong support for its business development in the Asia-Pacific region.
Upon completion, the new project will enable the Roche Diagnostics Asia-Pacific production base and R&D center to manufacture approximately 400 types of reagents and instruments. The total investment will reach1 billion Swiss francs. Mark Kay, General Manager of Roche Diagnostics Asia-Pacific Production Base and R&D Center, stated that the new investment project in Suzhou will provide more support for high-quality products to enter the Chinese market and ensure sustainable supply in the Asia-Pacific region.
Yao Guoliang, General Manager of Roche Diagnostics China, emphasized that China is one of Roche Diagnostics’ most strategically important markets globally. The company will adhere to the principle of “In China, for China” and continue to invest in local innovation, R&D, and production, tailoring innovative solutions for Chinese patients.
In his speech, Beat Bürgi, Swiss Ambassador to China, remarked that the openness, inclusiveness, and excellent business environment of Chinese cities like Suzhou have attracted numerous Swiss companies to establish themselves in China and thrive. He expressed confidence that with the deepening of Swiss-Chinese relations, more Swiss companies will achieve success in China.
Roche Diagnostics’ investment in Suzhou not only reflects the company’s confidence in the Chinese market but also reflects the rapid development and enormous market potential of China’s biopharmaceutical industry. In the future, as China’s healthcare system continues to improve and people’s living standards rise, the biopharmaceutical industry will enjoyeven greater development space.
【来源】http://www.chinanews.com/cj/2024/08-21/10272666.shtml
Views: 2